SCHEMBL6871762

SCHEMBL6871762

COc1cc(C(=O)NC2CCC(Nc3ccnc4cc(Cl)ccc34)CC2)cc(OC)c1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT5B Q4FZB7 1/20 0.58
KMT5C Q86Y97 1/20 0.58
GAK O14976 2/20 0.56
NSD2 O96028 1/20 0.55
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
KMT2A Q03164 1/20 0.51
CYP2D6 P10635 2/20 0.50
TACR2 P21452 1/20 0.50
TACR1 P25103 1/20 0.50
CYP2C19 P33261 1/20 0.50
CXCR6 O00574 7/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
RIPK2 O43353 1/20 0.46
COQ8A Q8NI60 1/20 0.46
NLK Q9UBE8 1/20 0.46
MAPK1 P28482 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6871766 1.00 KMT5B (0.58) KMT5BKMT5CGAKNSD2KDM4E
SCHEMBL6869524 0.91 KMT5B (0.58) KMT5BKMT5CGAKNSD2KDM4E
SCHEMBL6869523 0.91 KMT5B (0.58) KMT5BKMT5CGAKNSD2KDM4E
SCHEMBL6861878 0.89 KMT5B (0.56) KMT5BKMT5CGAKNSD2KDM4E
SCHEMBL6861873 0.89 KMT5B (0.56) KMT5BKMT5CGAKNSD2KDM4E
SCHEMBL6865726 0.89 KMT5B (0.57) KMT5BKMT5CNSD2KDM4EMEN1
SCHEMBL6865723 0.89 KMT5B (0.57) KMT5BKMT5CNSD2KDM4EMEN1
SCHEMBL6868160 0.87 KMT5B (0.57) KMT5BKMT5CGAKNSD2KDM4E
SCHEMBL6868174 0.87 KMT5B (0.57) KMT5BKMT5CNSD2KDM4EMEN1
SCHEMBL6868162 0.87 KMT5B (0.57) KMT5BKMT5CGAKNSD2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 US claimed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 US claimed
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 US disclosed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 US disclosed
WO-2003070244-A1 ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES ABBOTT LABORATORIES (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor MCHR1, MCHR2, MC1R KMT5B 1214/4885KMT5C 1285/4885GAK 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.